MET/HGF signaling pathway in ovarian carcinoma: Clinical implications and future direction

Paulette Mhawech-Fauceglia, Michelle Afkhami, Tanja Pejovic

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.

Original languageEnglish (US)
Article number960327
JournalPathology Research International
StatePublished - 2012

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'MET/HGF signaling pathway in ovarian carcinoma: Clinical implications and future direction'. Together they form a unique fingerprint.

Cite this